Cancer Research Campaign Technology Limited
Patent Applications and Registrations
Patent applications and USPTO patent grants for Cancer Research Campaign Technology Limited.The latest application filed is for "detection of dysplastic or neoplastic cells using anti-mcm2 antibodies".
Company Profile
0.37.2
- Cancer Research Campaign Technology Limited - London GB
- Cancer Research Campaign Technology Limited - CH CH
- Cancer Research Campaign Technology Limited -
- Cancer Research Campaign Technology Limited - GB GB
- Cancer Research Campaign Technology Limited - Lodnon GB2
- Cancer Research Campaign Technology, Ltd. - London GB
Patent Activity
| Patent | Date |
|---|---|
| Tricyclic inhibitors of poly(ADP-ribose) polymerases Grant 7,429,578 - Webber , et al. September 30, 2 | 2008-09-30 |
| Inhibitors of the interaction between P53 and MDM2 Grant 7,083,983 - Lane , et al. August 1, 2 | 2006-08-01 |
| Binding complexes Grant 7,018,791 - Willison , et al. March 28, 2 | 2006-03-28 |
| Tricyclic inhibitors of poly(ADP-ribose) polymerases Grant 6,977,298 - Webber , et al. December 20, 2 | 2005-12-20 |
| Nitrogen mustard compounds and prodrugs therefor Grant 6,852,755 - Springer , et al. February 8, 2 | 2005-02-08 |
| Cyclin dependent kinase inhibitors Grant 6,677,345 - Griffin , et al. January 13, 2 | 2004-01-13 |
| Detection of dysplastic or neoplastic cells using anti-MCM2 antibodies App 20030143646 - Laskey, Ronald A. ; et al. | 2003-07-31 |
| Papillomavirus L2 protein App 20020136736 - Jarrett, William F. H. ; et al. | 2002-09-26 |
| Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies Grant 6,303,323 - Laskey , et al. October 16, 2 | 2001-10-16 |
| Cyclin dependent kinase inhibiting purine derivatives Grant 6,303,618 - Griffin , et al. October 16, 2 | 2001-10-16 |
| Seco precursors of cyclopropylindolines and their use as prodrugs Grant 6,251,933 - Denny , et al. June 26, 2 | 2001-06-26 |
| Expression systems Grant 6,165,715 - Collins , et al. December 26, 2 | 2000-12-26 |
| Condensed N-aclyindoles as antitumor agents Grant 6,130,237 - Denny , et al. October 10, 2 | 2000-10-10 |
| Pyrimidine derivatives and guanine derivatives, and their use in treating tumor cells Grant 6,096,724 - McMurry , et al. August 1, 2 | 2000-08-01 |
| Global amplification of nucleic acids Grant 6,066,457 - Hampson , et al. May 23, 2 | 2000-05-23 |
| Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof Grant 6,045,997 - Futreal , et al. April 4, 2 | 2000-04-04 |
| 2-arylbenzazole compounds Grant 6,034,246 - Stevens , et al. March 7, 2 | 2000-03-07 |
| Surface expression of enzyme in gene directed prodrug therapy Grant 6,025,340 - Springer , et al. February 15, 2 | 2000-02-15 |
| Pharmaceuticals based on papillomaviruses Grant 6,020,309 - Campo , et al. February 1, 2 | 2000-02-01 |
| Nitrogen mustard prodrugs with novel lipophilic protecting groups, and processes for their production Grant 6,005,002 - Springer , et al. December 21, 1 | 1999-12-21 |
| Cyclopropylindoles and their seco precursors, and their use as prodrugs Grant 5,985,909 - Denny , et al. November 16, 1 | 1999-11-16 |
| Pyrimidine and purine derivatives and their use in treating tumour cells Grant 5,929,046 - McMurry , et al. July 27, 1 | 1999-07-27 |
| Antibody against carcionembryonic antigen (CEA) Grant 5,876,691 - Chester , et al. March 2, 1 | 1999-03-02 |
| Benzazole compounds Grant 5,874,431 - Stevens , et al. February 23, 1 | 1999-02-23 |
| 5T4 antigen from human trophoblasts Grant 5,869,053 - Stern , et al. February 9, 1 | 1999-02-09 |
| Light source Grant 5,843,143 - Whitehurst December 1, 1 | 1998-12-01 |
| 4-amino-fluorobenzamides and their use as cytotoxic prodrugs Grant 5,811,454 - Springer September 22, 1 | 1998-09-22 |
| Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form Grant 5,780,585 - Anlezark , et al. July 14, 1 | 1998-07-14 |
| Prodrugs of protein tyrosine kinase inhibitors Grant 5,728,868 - Springer , et al. March 17, 1 | 1998-03-17 |
| Drug delivery systems Grant 5,716,990 - Bagshawe , et al. February 10, 1 | 1998-02-10 |
| Focal neurographic magnetic resonance imaging system Grant 5,706,813 - Filler , et al. January 13, 1 | 1998-01-13 |
| Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form Grant 5,633,158 - Anlezark , et al. May 27, 1 | 1997-05-27 |
| Prodrugs for antibody directed enzyme prodrug therapy Grant 5,587,161 - Burke , et al. December 24, 1 | 1996-12-24 |
| Eicosapentaenoic acid used to treat cachexia Grant 5,457,130 - Tisdale , et al. October 10, 1 | 1995-10-10 |
| Chemical compounds Grant 5,405,990 - Burke , et al. April 11, 1 | 1995-04-11 |
| Biologically active material characterized by catabolic activity generally associated with cachexia-inducing tumors, preparations, production and uses thereof Grant 5,385,740 - Tisdale , et al. January 31, 1 | 1995-01-31 |
| Compounds having antitumor and antibacterial properties Grant 5,281,620 - Denny , et al. January 25, 1 | 1994-01-25 |
| Tetrazine derivatives Grant 5,260,291 - Lunt , et al. November 9, 1 | 1993-11-09 |
| Biologically active material characterized by catabolic activity generally associated with cachexia-inducing tumors, preparations, production and uses thereof Grant 5,219,579 - Tisdale , et al. June 15, 1 | 1993-06-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 